XOMA and Inveready Acquires Royalty Interest Position in Six Clinical-Stage Assets from Palobiofarma
Includes royalty interest in NIR178 September 30 2019 XOMA Corporation (NASDAQ: XOMA), announced today it has acquired a royalty interest in six clinical-stage assets targeting the adenosine...